GH Research PLCGHRS stock score: 42/100
$18.56 · +1.70% · Scored Nov 19, 2026
- Technical
- 44
- Fundamental
- 41
- News
- 50
The reading
GH Research (GHRS) scores 42 out of 100, which reads weak, higher than 28% of Healthcare stocks and 26% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 41, technicals 44.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Growth (Quarterly) at 1 weighs the most against it.
On the daily chart, trend-following indicators average 27 and contrarian oscillators 64 — a split worth reading before trusting the technical total.
News sentiment is neutral at 50; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 38 to 52, and it is down 6 points over the period.
About GH Research
GH Research (GHRS) is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that develops treatments for depression based on mebufotenin, also known as 5-MeO-DMT, a fast-acting psychedelic compound. Its lead candidate, GH001, is an inhaled form of mebufotenin given in an individualized dosing regimen within a single day, with the aim of producing rapid and lasting relief in patients with treatment-resistant depression without long in-clinic sessions. In a mid-stage trial, GH001 significantly reduced depression scores compared with placebo within days. After the U.S. Food and Drug Administration lifted a clinical hold on its U.S. application, the company is preparing a global late-stage program. GH Research is also developing GH002, an intravenous formulation of mebufotenin. It has no product revenue and funds development from cash raised from investors.
GH Research competes with Johnson & Johnson’s Spravato and with other companies developing psychedelic-based treatments for depression, including COMPASS Pathways, AtaiBeckley and MindMed. Its edge rests on a short-acting compound that may fit more easily into clinical practice than longer-acting psychedelics and on strong mid-stage efficacy data. Investors who follow GHRS stock tend to watch the start and progress of its late-stage trials. Interactions with the FDA and other regulators are closely followed. Safety findings, cash runway and the progress of competing psychedelic therapies are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward GHRS’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
41Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Net income growth from the prior fiscal year to the latest.
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
26 weighted scorers; 13 had no data today and are left out rather than counted as zero.
Technical · daily
31Pulling it up
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Money Flow Index (14-period) is a volume-weighted RSI that identifies overbought and oversold conditions.
The price change over the last 52 weeks.
Holding it back
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Simple Moving Average (100-period) provides a longer-term perspective on price trends.
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 50
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 50 | 1 |
| Daily | 31 | 3 |
| Weekly | 43 | 2 |
| Monthly | 60 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 42 |
| Nov 18, 2026 | 41 |
| Nov 15, 2026 | 41 |
| Nov 14, 2026 | 41 |
| Nov 13, 2026 | 41 |
| Nov 12, 2026 | 38 |
| Nov 11, 2026 | 42 |
| Nov 10, 2026 | 43 |
| Nov 7, 2026 | 41 |
| Nov 6, 2026 | 39 |
| Nov 5, 2026 | 40 |
| Nov 4, 2026 | 43 |
| Nov 3, 2026 | 45 |
| Nov 2, 2026 | 45 |
| Nov 1, 2026 | 45 |
| Oct 30, 2026 | 45 |
| Oct 29, 2026 | 44 |
| Oct 27, 2026 | 43 |
| Oct 26, 2026 | 42 |
| Oct 25, 2026 | 40 |
| Oct 24, 2026 | 40 |
| Oct 23, 2026 | 40 |
| Oct 22, 2026 | 41 |
| Oct 21, 2026 | 42 |
| Oct 20, 2026 | 41 |
| Oct 19, 2026 | 41 |
| Oct 18, 2026 | 40 |
| Oct 17, 2026 | 40 |
| Oct 16, 2026 | 40 |
| Oct 15, 2026 | 41 |
| Oct 14, 2026 | 40 |
| Oct 13, 2026 | 41 |
| Oct 12, 2026 | 42 |
| Oct 11, 2026 | 43 |
| Oct 10, 2026 | 43 |
| Oct 9, 2026 | 43 |
| Oct 8, 2026 | 43 |
| Oct 7, 2026 | 43 |
| Oct 6, 2026 | 43 |
| Oct 5, 2026 | 44 |
| Oct 4, 2026 | 45 |
| Oct 3, 2026 | 45 |
| Oct 2, 2026 | 45 |
| Oct 1, 2026 | 44 |
| Sep 30, 2026 | 45 |
| Sep 29, 2026 | 47 |
| Sep 28, 2026 | 45 |
| Sep 27, 2026 | 45 |
| Sep 26, 2026 | 45 |
| Sep 25, 2026 | 45 |
| Sep 24, 2026 | 46 |
| Sep 23, 2026 | 48 |
| Sep 22, 2026 | 49 |
| Sep 21, 2026 | 51 |
| Sep 20, 2026 | 50 |
| Sep 19, 2026 | 50 |
| Sep 18, 2026 | 50 |
| Sep 17, 2026 | 52 |
| Sep 16, 2026 | 49 |
| Sep 15, 2026 | 49 |
| Sep 14, 2026 | 49 |
| Sep 13, 2026 | 47 |
| Sep 12, 2026 | 47 |
| Sep 11, 2026 | 47 |
| Sep 10, 2026 | 48 |
| Sep 9, 2026 | 47 |
| Sep 8, 2026 | 50 |
| Sep 7, 2026 | 50 |
| Sep 6, 2026 | 50 |
| Sep 5, 2026 | 49 |
| Sep 4, 2026 | 49 |
| Sep 2, 2026 | 50 |
| Sep 1, 2026 | 49 |
| Aug 31, 2026 | 47 |
| Aug 30, 2026 | 49 |
| Aug 29, 2026 | 49 |
| Aug 28, 2026 | 48 |
| Aug 27, 2026 | 49 |
| Aug 26, 2026 | 50 |
| Aug 25, 2026 | 50 |
| Aug 24, 2026 | 48 |
| Aug 23, 2026 | 48 |
Key facts
- Market cap
- $1.3B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.32
- Risk grade (1–10)
- —
- Next earnings
- Nov 13, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| INVA Innoviva | $1.3B | 63 |
| LBRX LB Pharmaceuticals | $1.3B | 41 |
| OCUL Ocular Therapeutix | $1.3B | 38 |
| NVAX Novavax | $1.3B | 55 |
| MNKD MannKind | $1.3B | 56 |
| MLYS Mineralys Therapeutics | $1.3B | 31 |
Questions
What is GHRS's stock rating today?
GHRS scores 42/100 (Weak) as of Nov 19, 2026: technical 44, fundamental 41, and news sentiment 50, which is shown but not counted. Scores are recomputed every night.
What does GH Research do?
GH Research (GHRS) is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that develops treatments for depression based on mebufotenin, also known as 5-MeO-DMT, a fast-acting psychedelic compound. Its lead candidate, GH001, is an inhaled form of mebufotenin given in an individualized dosing regimen within a single day, with the aim of producing rapid and lasting relief in patients with treatment-resistant depression without long in-clinic sessions.
Is GHRS stock a buy?
The score is not a buy or sell recommendation. A 42 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the GHRS score calculated?
88 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/ghrs/"><img src="https://stocksscores.com/stocks/ghrs/badge.svg" alt="GHRS stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/ghrs/)